Therapeutic process with diphosphonate compounds
    3.
    发明授权
    Therapeutic process with diphosphonate compounds 失效
    二膦酸盐化合物的治疗过程

    公开(公告)号:US4371527A

    公开(公告)日:1983-02-01

    申请号:US208008

    申请日:1980-11-18

    IPC分类号: A61K31/66 C07F9/38 C07F9/40

    摘要: A method of increasing the quantity of circulating high density lipoproteins and clearing cholesterol from certain tissues, comprising administering to a human an effective amount of a compound of the formula ##STR1## where X is H, OH, ##STR2## or NH.sub.2 ; R and R' identical or different are H, CH.sub.3 or C.sub.2 H.sub.5 ; m is zero or 1; and A is selected from the group comprising (CH.sub.3).sub.3 C--, Y--C.sub.6 H.sub.4 --, Y--C.sub.6 H.sub.4 --O--C(CH.sub.3).sub.2 --, Y--C.sub.6 H.sub.4 --C(CH.sub.3).sub.2 --, Y--C.sub.6 H.sub.4 --C(O)--C.sub.6 H.sub.4 --, Y--C.sub.6 H.sub.4 --(CH.sub.2).sub.n -- and Y--C.sub.6 H.sub.4 --O--(CH.sub.2).sub.n --, where n is an integer from 1 to 6 and Y is H, CH.sub.3, OCH.sub.3 or Cl.The present invention is a division of our copending application Ser. No. 114,423, filed Jan. 22, 1980, now U.S. Pat. No. 4,309,364.

    Anti-atherosclerotic pharmaceutical compositions containing
diphosphonate compounds
    7.
    发明授权
    Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds 失效
    含有二膦酸盐化合物的抗动脉粥样硬化药物组合物

    公开(公告)号:US4416877A

    公开(公告)日:1983-11-22

    申请号:US310314

    申请日:1981-10-09

    IPC分类号: A61K31/66 C07F9/38 C07F9/40

    摘要: The present invention relates to a pharmaceutical composition for increasing the relative quantity of circulating high density lipoproteins favorable augmentating the alpha/beta lipoprotein cholesterol ratios and clearing cholesterol and lipids from certain tissues and inducing hypotensive activity comprising administering to a human an effective amount of a compound of the formula: ##STR1## where X is H, OH, or ##STR2## R and R' identical or different are H, CH.sub.3 or C.sub.2 H.sub.5 ; m is zero or 1; and A is selected from the group comprising (CH.sub.3).sub.3 C--, Y--C.sub.6 H.sub.4 --, Y--C.sub.6 H.sub.4 --O--C(CH.sub.3).sub.2 --, Y--C.sub.6 H.sub.4 --C(CH.sub.3).sub.2 --, Y--C.sub.6 H.sub.4 --C(O)--C.sub.6 H.sub.4 --, Y--C.sub.6 H.sub.4 --(CH.sub.2).sub.n -- and Y--C.sub.6 H.sub.4 --O--(CH.sub.2).sub.n --, where n is an integer from 1 to 6 and Y is H, CH.sub.3, OCH.sub.3, a halogen, and a pharmaceutically acceptable excipient.

    摘要翻译: 本发明涉及用于增加循环高密度脂蛋白的相对量的药物组合物,其有利地增加了α/β脂蛋白胆固醇比例,并且从某些组织中清除胆固醇和脂质并诱导降血压活性,包括向人施用有效量的化合物 其中X是H,OH或R 1和R 3相同或不同的是H,CH 3或C 2 H 5; m为零或1; 并且A选自(CH 3)3C-,Y-C 6 H 4 - ,Y-C 6 H 4 -OC(CH 3)2 + 13,Y-C 6 H 4 -C(CH 3)2 - ,Y-C 6 H 4 -C(O) -C 6 H 4 - ,Y-C 6 H 4 - (CH 2)n - 和Y-C 6 H 4 -O-(CH 2)n - ,其中n是1至6的整数,Y是H,CH 3,OCH 3,卤素和药学上 可接受的赋形剂。